UK MHRA · August 18, 2026

UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

Original title: Policy paper: UK Position Paper on Microbiome-Based Medicinal Products (MBMPs)

MHRA guidance to support development and licensing of microbiome-based medicinal products in the UK.

High obligation Sector Pharmaceuticals UK Pharmaceuticals

MHRA position paper, to help encourage the development and licensing of Microbiome-Based Medicinal Products (MBMPs) products in the UK.

Read the official source ↗

Published by UK MHRA. HealthSignal links to the original document; the summary above is extracted from the source text.